Acquired TPM3::NTRK1 fusion as a novel off-target resistance mechanism to selpercatinib in RET-positive lung adenocarcinoma: a case report.

Vitrakvi (larotrectinib) - Bayer

Retevmo (selpercatinib) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42729323

Abhinav Dewan; Mansi Sharma; Priyanka Venkatraman; Ritwika Choudhury; Sabeena K Choudhary; Ullas Batra; Vivek Subbiah

Sep 13, 2026